-
1
-
-
0037189401
-
Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning
-
DOI 10.1126/science.1070104
-
A. Aiuti Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning Science 296 5577 2002 2410 2413 (Pubitemid 34734219)
-
(2002)
Science
, vol.296
, Issue.5577
, pp. 2410-2413
-
-
Aiuti, A.1
Slavin, S.2
Aker, M.3
Ficara, F.4
Deola, S.5
Mortellaro, A.6
Morecki, S.7
Andolfi, G.8
Tabucchi, A.9
Carlucci, F.10
Marinello, E.11
Cattaneo, F.12
Vai, S.13
Servida, P.14
Miniero, R.15
Roncarolo, M.G.16
Bordignon, C.17
-
2
-
-
44049106551
-
Potential of AAV vectors in the treatment of metabolic disease
-
DOI 10.1038/gt.2008.64, PII GT200864, Special Issue: AAV Vectors for Clinical GeneTherapy
-
I.E. Alexander Potential of AAV vectors in the treatment of metabolic disease Gene Ther. 15 2008 831 839 (Pubitemid 351712616)
-
(2008)
Gene Therapy
, vol.15
, Issue.11
, pp. 831-839
-
-
Alexander, I.E.1
Cunningham, S.C.2
Logan, G.J.3
Christodoulou, J.4
-
4
-
-
70449427834
-
Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy
-
N. Cartier Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy Science 326 2009 818 823
-
(2009)
Science
, vol.326
, pp. 818-823
-
-
Cartier, N.1
-
5
-
-
84857599096
-
-
CAT monthly reports published on the EMA website
-
CAT monthly reports published on the EMA website. http://www.ema.europa. eu/ema/index.jsp?curl=pages/news-and-events/document-listing/ document-listing-000196.jsp&murl=menus/about-us/about-us.jsp&mid= WC0b01ac05800292a8
-
-
-
-
6
-
-
77249084198
-
CAT - The new committee for advanced therapies at the European Medicines Agency
-
P. Celis CAT - The new committee for advanced therapies at the European Medicines Agency Bundesgesundheitsblatt 53 2010 9 13
-
(2010)
Bundesgesundheitsblatt
, vol.53
, pp. 9-13
-
-
Celis, P.1
-
7
-
-
84857525350
-
Commission Directive 2003/94/EC of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use
-
14 October
-
Commission Directive 2003/94/EC of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use. Official J. Eur. UnionL 262, 14 October 2003, p 24. http://ec.europa.eu/health/ files/eudralex/vol-1/dir-2003-94/dir-2003-94-en.pdf
-
(2003)
Official J. Eur. UnionL
, vol.262
, pp. 24
-
-
-
8
-
-
33748267129
-
Commission Recommendation 2003/361/EC of 6 May 2003 concerning the definition of micro, small and medium-sized enterprises
-
20 May
-
Commission Recommendation 2003/361/EC of 6 May 2003 concerning the definition of micro, small and medium-sized enterprises. Official J. Eur. UnionL 124, 20 May 2003, p. 36. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri= OJ:L:2003:124:0036:0041:en:PDF
-
(2003)
Official J. Eur. UnionL
, vol.124
, pp. 36
-
-
-
9
-
-
29344453431
-
Commission Directive 2005/28/EC of 8 April 2005 laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorisation of the manufacturing or importation of such products
-
9 April
-
Commission Directive 2005/28/EC of 8 April 2005 laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorisation of the manufacturing or importation of such products. Official J. Eur. UnionL 91, 9 April 2003, p. 13. http://ec.europa.eu/health/files/eudralex/vol-1/dir- 2005-28/dir-2005-28-en.pdf
-
(2003)
Official J. Eur. UnionL
, vol.91
, pp. 13
-
-
-
10
-
-
0012111484
-
Directive 2001/83/EC of the European Parliament and the Council of 13 November 2007 on the Community code relating to medicinal products for human use
-
28 November Consolidated version 05/10/2009
-
Directive 2001/83/EC of the European Parliament and the Council of 13 November 2007 on the Community code relating to medicinal products for human use. Official J. Eur. UnionL 311, 28 November 2001, p. 67. Consolidated version 05/10/2009. http://ec.europa.eu/health/files/eudralex/vol-1/reg-2008-1234/reg- 2008-1234-en.pdf
-
(2001)
Official J. Eur. UnionL
, vol.311
, pp. 67
-
-
-
11
-
-
84857599095
-
-
EMA/CAT/235374/2010: Committee for Advanced Therapies (CAT) Work Programme 2010-2015
-
EMA/CAT/235374/2010: Committee for Advanced Therapies (CAT) Work Programme 2010-2015. http://www.ema.europa.eu/docs/en-GB/document-library/Work- programme/2010/11/WC500099029.pdf
-
-
-
-
17
-
-
84857608996
-
-
Innovation Task Force (ITF)
-
Innovation Task Force (ITF). http://www.ema.europa.eu/ema/index.jsp?curl= pages/regulation/general/general-content-000334.jsp&murl=menus/regulations/ regulations.jsp&mid=WC0b01ac05800ba1d9
-
-
-
-
18
-
-
77249171677
-
Legal basis of the Advanced Therapies Regulation
-
V. Jekerle Legal basis of the Advanced Therapies Regulation Bundesgesundheitsblatt 53 2010 4 8
-
(2010)
Bundesgesundheitsblatt
, vol.53
, pp. 4-8
-
-
Jekerle, V.1
-
19
-
-
77949327872
-
Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils
-
E.M. Kang Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils Blood 115 4 2010 783 791
-
(2010)
Blood
, vol.115
, Issue.4
, pp. 783-791
-
-
Kang, E.M.1
-
20
-
-
34250683023
-
Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: An open label, phase I trial
-
DOI 10.1016/S0140-6736(07)60982-9, PII S0140673607609829
-
M.G. Kaplitt Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: An open label, phase I trial Lancet 369 2007 2097 2105 (Pubitemid 46935946)
-
(2007)
Lancet
, vol.369
, Issue.9579
, pp. 2097-2105
-
-
Kaplitt, M.G.1
Feigin, A.2
Tang, C.3
Fitzsimons, H.L.4
Mattis, P.5
Lawlor, P.A.6
Bland, R.J.7
Young, D.8
Strybing, K.9
Eidelberg, D.10
During, M.J.11
-
21
-
-
76949104143
-
Factors associated with success of marketing authorization applications for pharmaceutical drugs submitted to the European Medicines Agency
-
J. Regnstom Factors associated with success of marketing authorization applications for pharmaceutical drugs submitted to the European Medicines Agency Eur. J. Clin. Pharmacol. 66 1 2009 39 48
-
(2009)
Eur. J. Clin. Pharmacol.
, vol.66
, Issue.1
, pp. 39-48
-
-
Regnstom, J.1
-
22
-
-
77958499413
-
Regulation (EC) No. 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No. 726/2004
-
10 December
-
Regulation (EC) No. 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No. 726/2004. Official J. Eur. UnionL 324, 10 December 2007, p. 121
-
(2007)
Official J. Eur. UnionL
, vol.324
, pp. 121
-
-
-
23
-
-
0003187521
-
Regulation (EC) No. 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products
-
22 January
-
Regulation (EC) No. 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Official J. Eur. UnionL 18, 22 January 2000, p. 1. http://ec.europa.eu/health/files/eudralex/vol- 1/reg-2000-141/reg-2000-141-en.pdf
-
(2000)
Official J. Eur. UnionL
, vol.18
, pp. 1
-
-
-
24
-
-
6344263893
-
Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy
-
DOI 10.1089/hum.2004.15.1065
-
N.B. Romero Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy Hum. Gene Ther. 15 2004 1065 1076 (Pubitemid 39552288)
-
(2004)
Human Gene Therapy
, vol.15
, Issue.11
, pp. 1065-1076
-
-
Romero, N.B.1
Braun, S.2
Benveniste, O.3
Leturcq, F.4
Hogrel, J.-Y.5
Morris, G.E.6
Barois, A.7
Eymard, B.8
Payan, C.9
Ortega, V.10
Boch, A.-L.11
Lejean, L.12
Thioudellet, C.13
Mourot, B.14
Escot, C.15
Choquel, A.16
Recan, D.17
Kaplan, J.-C.18
Dickson, G.19
Klatzmann, D.20
Molinier-Frenckel, V.21
Guillet, J.-G.22
Squiban, P.23
Herson, S.24
Fardeau, M.25
more..
-
25
-
-
77649194372
-
Challenges with advanced therapy medicinal products and how to meet them
-
C.K. Schneider Challenges with advanced therapy medicinal products and how to meet them Nat. Rev. Drug Discov. 9 3 2010 195 201
-
(2010)
Nat. Rev. Drug Discov.
, vol.9
, Issue.3
, pp. 195-201
-
-
Schneider, C.K.1
-
26
-
-
78649451337
-
The different extent of B and T cell immune reconstitution after hematopoietic stem cell transplantation and enzyme replacement therapies in SCID patients with adenosine deaminase deficiency
-
F. Serana The different extent of B and T cell immune reconstitution after hematopoietic stem cell transplantation and enzyme replacement therapies in SCID patients with adenosine deaminase deficiency J. Immunol. 185 2010 7713 7722
-
(2010)
J. Immunol.
, vol.185
, pp. 7713-7722
-
-
Serana, F.1
|